Tesamorelin – 5MG/10MG

Scientific Overview of Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been structurally modified to enhance its stability and duration of activity. It is considered part of a class of GHRH derivatives that have been studied for their influence on growth hormone release and downstream pathways. Research suggests that Tesamorelin may share mechanistic similarities with other GHRH analogs such as CJC-1295, GRF (1-29), and Sermorelin. The modification at its N-terminal region appears to prolong its activity, while also maintaining a resemblance to the physiological patterns of GHRH action.

Alternative Names: TH9507

Tesamorelin Studies and Research Data

Interaction with the Pituitary Axis

Tesamorelin has been investigated for its potential interactions with GHRH receptors in the pituitary gland. Experimental findings suggest that Tesamorelin may initiate conformational changes in receptor structures, which could open intracellular binding sites for secondary signaling proteins. This sequence may stimulate cyclic adenosine monophosphate (cAMP) production and activate protein kinase pathways, potentially leading to growth hormone release from pituitary somatotrophs. Research also indicates associated increases in insulin-like growth factor 1 (IGF-1), hinting at possible downstream metabolic signaling effects.

Tesamorelin Explorations in Metabolic Redistribution

A primary area of research into Tesamorelin has focused on its potential role in regulating adipose distribution, particularly in visceral compartments. Studies suggest that Tesamorelin may be associated with notable reductions in visceral adiposity, in some cases accompanied by reductions in triglycerides and cholesterol fractions. Broader reviews indicate a potential trend toward improved metabolic markers, although outcomes vary depending on study duration and model conditions.

Nervous System Investigations

Tesamorelin has been examined in connection with nervous system processes. Research exploring peripheral nerve injury suggests that manipulation of the growth hormone axis might support nerve repair, and Tesamorelin has been included in experimental models investigating this possibility. Additional studies have considered its potential role in neurodegenerative research, particularly in relation to cognitive processes, where shifts in neurotransmitter balance such as GABA and myo-inositol have been observed.

Muscle Structure and Tissue Quality

Investigations using imaging technology have suggested Tesamorelin may influence muscle density and composition. Observed outcomes include potential increases in muscle area as well as decreases in intramuscular fat content. These findings have led to further interest in Tesamorelin’s possible role in regulating body composition through indirect pathways linked to growth hormone stimulation.

Tesamorelin Studies in Hepatic and Lipid Biology

Research on liver tissue suggests Tesamorelin may reduce hepatic fat accumulation in certain experimental conditions. Some findings note reductions in liver fat fractions and slower progression of fibrotic changes, along with trends toward lowered markers of systemic inflammation. Despite these observations, Tesamorelin appears to show little consistent influence on key liver enzyme levels, suggesting selective rather than broad effects.

Endocrine Considerations in Specific Models

In research involving immune-related conditions, Tesamorelin has been studied for its potential to counter altered pituitary function and growth hormone deficiency. This line of investigation points to possible compensatory actions through its influence on natural growth hormone rhythms, though variability across experimental groups is reported.

Conclusion

Research into Tesamorelin suggests that it may influence multiple biological systems through its interaction with the growth hormone axis. Areas of interest include adipose redistribution, liver fat reduction, muscle quality, nervous system repair, and cognitive pathways. While findings point to several promising directions, outcomes remain model-dependent, and continued research is required to clarify the broader implications.

References

1. Stanley, T. L., Falutz, J., Marsolais, C., Morin, J., Soulban, G., Mamputu, J. C., Assaad, H., Turner, R., & Grinspoon, S. K. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving Tesamorelin. Clinical Infectious Diseases, 54(11), 1642–1651.
2. Friedman, S. D., Baker, L. D., Borson, S., Jensen, J. E., Barsness, S. M., Craft, S., Merriam, G. R., Otto, R. K., Novotny, E. J., & Vitiello, M. V. (2013). Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology, 70(7), 883–890.
3. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 357(23), 2359–2370.
4. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology & Metabolism, 96(1), 150-8.
5. Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy, 46(2), 240–247.
6. Sivakumar T, Mechanic O, Fehmie DA, Paul B. (2011). Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Medicine, 12(8), 453-62.
7. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. (2019). Effects of Tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV, 6(12), e821–e830.
8. Mangili, A., Falutz, J., Mamputu, J. C., Stepanians, M., & Hayward, B. (2015). Predictors of Treatment Response to Tesamorelin in HIV-Infected Patients with Excess Abdominal Fat. PLOS One, 10(10), e0140358.
9. Zhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., ... Wang, M. W. (2020). Structural basis for activation of the growth hormone-releasing hormone receptor. Nature Communications, 11(1).
10. Tuffaha, S. H., Singh, P., Budihardjo, J. D., Means, K. R., Higgins, J. P., Shores, J. T., Salvatori, R., Höke, A., Lee, W. P., & Brandacher, G. (2016). Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert Opinion on Therapeutic Targets, 20(10), 1259–1265.
11. Rochira, V., & Guaraldi, G. (2017). Growth hormone deficiency and human immunodeficiency virus. Best Practice & Research Clinical Endocrinology & Metabolism, 31(1), 91–111.
12. Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. (2019). Tesamorelin decreases muscle fat and increases muscle area in adults with HIV. Journal of Frailty & Aging, 8(3), 154-159.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.